Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 792.33

+1.8%

2:50 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Patrick Slevin who started this subject	3/11/2002 8:40:58 PM
From: Miljenko Zuanic	Read Replies (1) of 3561

reutershealth.com Obesity In a 2001 study of nearly 85,000 nurses, obesity was the number one risk factor for diabetes type 2. It is estimated that 80% to 95% of the current dramatic increases in type 2 diabetes is due to obesity and having excess fat in the abdominal region. Excess body fat appears to play a strong role in insulin resistance, but the way the fat is distributed is also significant. Weight concentrated around the abdomen and in the upper part of the body (apple-shaped) is associated with insulin resistance and diabetes, heart disease, high blood pressure, stroke, and unhealthy cholesterol levels. Fat that settles in a "pear-shape" around the hips and flank appears to have a lower association with these conditions. One study suggested that waist circumferences greater than 35 inches in women and 40 inches in men signify increased risk for heart disease and diabetes. Of note, however, obesity does not explain all cases of diabetes type 2, which is also common among people in countries where weights tend to be low, such as Asia or India.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next